Malignant Pleural Mesothelioma: Patient Selection for Extrapleural Pneumonectomy

  • David A. Waller


The selection of patients with malignant pleural mesothelioma (MPM) for extrapleural pneumonectomy (EPP) can be considered in two areas: resectability and operability. Resectability refers to the ability to achieve macroscopic tumor clearance. Operability refers to the patient’s fitness to tolerate the operation.


  1. 1.
    Rusch VW, Godwin JD, Shuman WP. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1988;96:171–177.PubMedGoogle Scholar
  2. 2.
    Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039–1047.PubMedCrossRefGoogle Scholar
  3. 3.
    Stewart D, Waller D, Edwards J, Jeyapalan K, Entwisle J. Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma? Eur J Cardiothorac Surg. 2003;24:1019–1024.PubMedCrossRefGoogle Scholar
  4. 4.
    Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126:11–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, Rusch VW Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2006;132:763–768.PubMedCrossRefGoogle Scholar
  6. 6.
    Pilling JE, Stewart DJ, Martin-Ucar AE, Muller S, O’Byrne KJ, Waller DA. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2004;25:497–501.PubMedCrossRefGoogle Scholar
  7. 7.
    Rice DC, Steliga MA, Stewart J, Eapen G, Jimenez CA, Lee JH, Hofstetter WL, Marom EM, Mehran RJ, Vaporciyan AA, Walsh GL, Swisher SG. Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg. 2009;88:862–868.PubMedCrossRefGoogle Scholar
  8. 8.
    de Perrot M, Uy K, Anraku M, Tsao MS, Darling G, Waddell TK, Pierre AF, Bezjak A, Keshavjee S, Johnston MR. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2007;133:111–116.PubMedCrossRefGoogle Scholar
  9. 9.
    Edwards JG, Stewart DJ, Martin-Ucar A, Muller S, Richards C, Waller DA. The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma. J Thorac Cardiovasc Surg. 2006;131:981–987.PubMedCrossRefGoogle Scholar
  10. 10.
    Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Flores RM, Routledge T, Seshan VE, Dycoco J, Zakowski M, Hirth Y, Rusch VW The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2008;136:605–610.PubMedCrossRefGoogle Scholar
  12. 12.
    Martin-Ucar AE, Nakas A, Edwards JG, Waller DA. Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2007;31:765–770.PubMedCrossRefGoogle Scholar
  13. 13.
    Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–626.PubMedCrossRefGoogle Scholar
  14. 14.
    Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1998;115:310–317.PubMedCrossRefGoogle Scholar
  15. 15.
    Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS, Walsh GL, Swisher SG, Hofstetter WL, Ordonez NG, Smythe WR. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005;80:1988–1992.PubMedCrossRefGoogle Scholar
  16. 16.
    Alvarez JM, Hasani A, Segal A, Sterret G, Millward M, Nowak A, Musk W, Bydder S. Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg. 2009;79:734–738.PubMedCrossRefGoogle Scholar
  17. 17.
    Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R, Ris HB, Jermann M, Mingrone W, Roth AD, Spiliopoulos A. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196–1202.PubMedCrossRefGoogle Scholar
  18. 18.
    Yan TD, Boyer M, Tin MM, Sim J, Kennedy C, McLean J, Bannon PG, McCaughan BC. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Ann Thorac Surg. 2009;87:1552–1556.PubMedCrossRefGoogle Scholar
  19. 19.
    Balduyck B, Trousse D, Nakas A, Martin-Ucar AE, Edwards J, Waller DA. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? Ann Thorac Surg. 2010;89:907–911.PubMedCrossRefGoogle Scholar
  20. 20.
    Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–3013.PubMedCrossRefGoogle Scholar
  21. 21.
    Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol. 2008;3:851–857.PubMedCrossRefGoogle Scholar
  22. 22.
    Gordon GJ, Dong L, Yeap BY, Richards WG, Glickman JN, Edenfield H, Mani M, Colquitt R, Maulik G, Van Oss B, Sugarbaker DJ, Bueno R. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst. 2009;101:678–686.PubMedCrossRefGoogle Scholar
  23. 23.
    Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT; American College of Chest Physicians. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):161S–177S.PubMedCrossRefGoogle Scholar
  24. 24.
    Win T, Tasker AD, Groves AM, White C, Ritchie AJ, Wells FC, Laroche CM. Ventilation-perfusion scintigraphy to predict postoperative pulmonary function in lung cancer patients undergoing pneumonectomy. AJR Am J Roentgenol. 2006;187:1260–1265.PubMedCrossRefGoogle Scholar
  25. 25.
    Sugarbaker DJ, Jaklitsch MT, Bueno R, Richards W, Lukanich J, Mentzer SJ, Colson Y, Linden P, Chang M, Capalbo L, Oldread E, Neragi-Miandoab S, Swanson SJ, Zellos LS. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–146.PubMedCrossRefGoogle Scholar
  26. 26.
    Stewart DJ, Martin-Ucar AE, Edwards JG, West K, Waller DA. Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations. Eur J Cardiothorac Surg. 2005;27:373–378.PubMedCrossRefGoogle Scholar
  27. 27.
    Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol. 2008;3:1325–1331.PubMedCrossRefGoogle Scholar
  28. 28.
    Treasure T, Waller D, Tan C, Entwisle J, O’Brien M, O’Byrne K, Thomas G, Snee M, Spicer J, Landau D, Lang-Lazdunski L, Bliss J, Peckitt C, Rogers S, Marriage Nee Denholm E, Coombes G, Webster-Smith M, Peto J. The mesothelioma and radical surgery randomized controlled trial: the MARS feasibility study. J Thorac Oncol. 2009 Aug 5. [Epub ahead of print].Google Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • David A. Waller
    • 1
  1. 1.Department of Thoracic SurgeryGlenfield HospitalLeicesterUK

Personalised recommendations